Limits...
Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase.

Hwang IY, Jeong CS - Biomol Ther (Seoul) (2015)

Bottom Line: It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump).Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner.Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

View Article: PubMed Central - PubMed

Affiliation: College of Pharmacy, Duksung Women's University, Seoul 132-714, Republic of Korea.

ABSTRACT
Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

No MeSH data available.


Related in: MedlinePlus

Effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer in rats. The values are mean ± S.E.M. of 6 animals. Significant difference *p<0.05; **p<0.001 compared to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556206&req=5

f3-bt-23-458: Effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer in rats. The values are mean ± S.E.M. of 6 animals. Significant difference *p<0.05; **p<0.001 compared to the control group.

Mentions: The effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer were also investigated; results are shown in Table 2 and Fig. 3. Sennoside A and sennoside B were administered orally to examine their inhibitory effects on indomethacin-induced gastric lesions. The lesion index in the controls was 29.7 ± 3.1 mm, whereas in the sennoside A and B (100 mg/kg) treated groups lesion indices were 19.0 ± 14.1 mm and 11.0 ± 4.2 mm, that is, inhibitions of 36.0% and 62.9%, respectively. Furthermore, sennoside B was found to have a better effect than cimetidine (150 mg/kg; the positive control), which inhibited lesion development by 43.0%.


Gastroprotective Activities of Sennoside A and Sennoside B via the Up-Regulation of Prostaglandin E2 and the Inhibition of H(+)/K(+)-ATPase.

Hwang IY, Jeong CS - Biomol Ther (Seoul) (2015)

Effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer in rats. The values are mean ± S.E.M. of 6 animals. Significant difference *p<0.05; **p<0.001 compared to the control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556206&req=5

f3-bt-23-458: Effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer in rats. The values are mean ± S.E.M. of 6 animals. Significant difference *p<0.05; **p<0.001 compared to the control group.
Mentions: The effects of sennoside A and sennoside B on indomethacin-induced gastric ulcer were also investigated; results are shown in Table 2 and Fig. 3. Sennoside A and sennoside B were administered orally to examine their inhibitory effects on indomethacin-induced gastric lesions. The lesion index in the controls was 29.7 ± 3.1 mm, whereas in the sennoside A and B (100 mg/kg) treated groups lesion indices were 19.0 ± 14.1 mm and 11.0 ± 4.2 mm, that is, inhibitions of 36.0% and 62.9%, respectively. Furthermore, sennoside B was found to have a better effect than cimetidine (150 mg/kg; the positive control), which inhibited lesion development by 43.0%.

Bottom Line: It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump).Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner.Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

View Article: PubMed Central - PubMed

Affiliation: College of Pharmacy, Duksung Women's University, Seoul 132-714, Republic of Korea.

ABSTRACT
Sennoside A (erythro) and sennoside B (threo) are dianthrone glycosides and diastereomers. We investigated their abilities to prevent the gastric lesions associated with diseases, such as, gastritis and gastric ulcer. To elucidate their gastroprotective effects, the inhibitions of HCl•EtOH-induced gastritis and indomethacin-induced gastric ulcers were assessed in rats. It was observed that both sennoside A and sennoside B increased prostaglandin E2 (PGE2) levels and inhibited H(+)/K(+)-ATPase (proton pump). In a rat model, both compounds reduced gastric juice, total acidity and increased pH, indicating that proton pump inhibition reduces gastric acid secretion. Furthermore, sennoside A and B increased PGE2 in a concentration-dependent manner. In a gastric emptying and intestinal transporting rate experiment, both sennoside A and sennoside B accelerated motility. Our results thus suggest that sennoside A and sennoside B possess significant gastroprotective activities and they might be useful for the treatment of gastric disease.

No MeSH data available.


Related in: MedlinePlus